Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Takes “Blank Check” Approach To Pursuit Of Biotech Agreements

Executive Summary

GlaxoSmithKline will continue to actively build its biotech business with further product in-licensing and acquisitions, CEO J.P. Garnier indicated

You may also be interested in...



Future Vaccine Growth Could Come From Recent Biotech Entrants – Tufts

The potential to create novel, innovative products has made the vaccine market more attractive in recent years, drawing new entrants as well as a resurgence of interest from traditional vaccine manufacturers, Tufts Center for the Study of Drug Development Director Kenneth Kaitin suggests

Future Vaccine Growth Could Come From Recent Biotech Entrants – Tufts

The potential to create novel, innovative products has made the vaccine market more attractive in recent years, drawing new entrants as well as a resurgence of interest from traditional vaccine manufacturers, Tufts Center for the Study of Drug Development Director Kenneth Kaitin suggests

Collaboration Deals With Pharma May Be Preferable To Licensing For Biotech

Biotechs may want to look at deal structures with pharmaceutical companies outside of the traditional licensing model in order to have greater control over the development process, Medarex Senior Director of Development Melinda Shockley said at the recent Drug Information Association annual meeting in Philadelphia

Related Content

UsernamePublicRestriction

Register

PS046758

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel